SUMOylation by SUMO2 is implicated in the degradation of misfolded ataxin-7 via RNF4 in SCA7 models by Marinello, Martina et al.
  
 University of Groningen
SUMOylation by SUMO2 is implicated in the degradation of misfolded ataxin-7 via RNF4 in
SCA7 models
Marinello, Martina; Werner, Andreas; Giannone, Mariagiovanna; Tahiri, Khadija; Alves,
Sandro; Tesson, Christelle; den Dunnen, Wilfred; Seeler, Jacob-S; Brice, Alexis; Sittler, Annie
Published in:
Disease models & mechanisms
DOI:
10.1242/dmm.036145
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Marinello, M., Werner, A., Giannone, M., Tahiri, K., Alves, S., Tesson, C., ... Sittler, A. (2019). SUMOylation
by SUMO2 is implicated in the degradation of misfolded ataxin-7 via RNF4 in SCA7 models. Disease
models & mechanisms, 12(1). https://doi.org/10.1242/dmm.036145
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
RESEARCH ARTICLE
SUMOylation by SUMO2 is implicated in the degradation of
misfolded ataxin-7 via RNF4 in SCA7 models
Martina Marinello1,2,*, Andreas Werner3, Mariagiovanna Giannone1,2, Khadija Tahiri1, Sandro Alves1,
Christelle Tesson1,2, Wilfred den Dunnen4, Jacob-S. Seeler5, Alexis Brice1,6 and Annie Sittler1,‡,§
ABSTRACT
Perturbation of protein homeostasis and aggregation of misfolded
proteins is a major cause of many human diseases. A hallmark of the
neurodegenerative disease spinocerebellar ataxia type 7 (SCA7) is the
intranuclear accumulation of mutant, misfolded ataxin-7 (polyQ-
ATXN7). Here, we show that endogenous ATXN7 is modified by
SUMO proteins, thus also suggesting a physiological role for this
modification under conditions of proteotoxic stress caused by the
accumulation of polyQ-ATXN7. Co-immunoprecipitation experiments,
immunofluorescence microscopy and proximity ligation assays
confirmed the colocalization and interaction of polyQ-ATXN7 with
SUMO2 in cells. Moreover, upon inhibition of the proteasome, both
endogenous SUMO2/3 and the RNF4 ubiquitin ligase surround large
polyQ-ATXN7 intranuclear inclusions. Overexpression of RNF4
and/or SUMO2 significantly decreased levels of polyQ-ATXN7 and,
upon proteasomal inhibition, led to a marked increase in the
polyubiquitination of polyQ-ATXN7. This provides a mechanism for
the clearance of polyQ-ATXN7 from affected cells that involves the
recruitment of RNF4 by SUMO2/3-modified polyQ-ATXN7, thus
leading to its ubiquitination and proteasomal degradation. In a SCA7
knock-in mouse model, we similarly observed colocalization of
SUMO2/3 with polyQ-ATXN7 inclusions in the cerebellum and retina.
Furthermore, we detected accumulation of SUMO2/3 high-molecular-
mass species in the cerebellum of SCA7 knock-inmice, comparedwith
their wild-type littermates, and changes in SUMO-related transcripts.
Immunohistochemical analysis showed the accumulation of SUMO
proteins and RNF4 in the cerebellum of SCA7 patients. Taken
together, our results show that the SUMO pathway contributes to the
clearance of aggregated ATXN7 and suggest that its deregulation
might be associated with SCA7 disease progression.
KEY WORDS: Polyglutamine disease, SCA7, SUMO, Proteasome,
RNF4
INTRODUCTION
Spinocerebellar ataxia type 7 (SCA7) is an inherited neurological
disorder characterized by severe loss of neurons in the cerebellum
and associated structures, as well as macular degeneration (David
et al., 1997; Michalik et al., 2003).
SCA7 is one of nine polyglutamine (polyQ) neurodegenerative
disorders, and is caused by CAG/polyQ repeat expansions in the
ataxin-7 (ATXN7) gene. The polyQ stretch of the ATXN7 protein in
healthy individuals consists of 4-35 glutamines, but is expanded to
37->400 glutamines in patients (David et al., 1997; Stevanin et al.,
1998; van de Warrenburg et al., 2001).
ATXN7 plays a role in the regulation of transcription, as it is a
component of the co-activator multi-protein complex SAGA,
involved in histone acetylation (Mohan et al., 2014). Mutant
(polyQ) ATXN7 accumulates in the nucleus and forms intranuclear
neuronal inclusions due to its polyQ content. These inclusions
contain other transcriptional activators or repressors, as well as
chaperones, proteasome subunits, promyelocytic leukemia protein
(PML) and proteins implicated in post-translational modifications,
such as ubiquitin and the small ubiquitin-like modifier (SUMO)
proteins (Janer et al., 2010; Takahashi et al., 2003).
Clastosomes were first described by Lafarga et al. (2002) as a
subset of PML nuclear bodies that contain components of the
ubiquitin-proteasome pathway, including the active 20S core and
the 19S regulatory subunits of the proteasome, as well as substrates,
such as short-lived transcription factors. Normally scarce, these
structures form in response to stimuli that activate proteasome-
dependent proteolysis and disappear when proteasome function
is inhibited.
SUMOylation is the covalent attachment of a small ubiquitin-
related SUMO protein to specific lysine residues in target proteins.
This reversible modification is a significant regulatory mechanism
of normal cell function, in particular nuclear signaling or transport,
transcriptional regulation, protein stability, and DNA replication
or repair (Flotho and Melchior, 2013). Mammals express four
∼100-amino-acid SUMO proteins: SUMO1, SUMO2 and SUMO3
[the latter two often referred to as one protein, SUMO2/3 (with 97%
identical residues)], and SUMO4. Although SUMO1 and SUMO2/3
use the same enzymatic conjugation pathway, they serve different
functions as the various isoforms can be conjugated to different
target proteins (Saitoh and Hinchey, 2000; Vertegaal et al., 2006).
Furthermore, the ubiquitin-proteasome system acts in a cooperative
manner with SUMO2/3 modification (Schimmel et al., 2008), thus
linking this specific SUMOylation pathway to protein degradation.
SUMO2/3 chains serve as docking sites for RNF4, which earmarks
the misfolded proteins for proteasomal degradation by adding
a ubiquitin tag. This mechanism was first described in acuteReceived 26 June 2018; Accepted 4 December 2018
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promyelocytic leukemia, which can be treated with arsenic, which
induces polySUMOylation of PML, recognition by RNF4,
subsequent polyubiquitination and proteasomal degradation
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). The
multi-step SUMOylation process requires E1, E2 and E3 activities.
In mammals, there is a single E1-activating enzyme, and a single
E2-conjugating enzyme (UBC9), but multiple E3 ligases, which
provide substrate specificity (Andrews et al., 2005; Kahyo et al.,
2001; Pichler et al., 2002). SUMOylation is usually very transient
and is reversed by SUMO proteases, e.g. of the SENP family, in
such a way that they both cleave the SUMO moiety from its target
protein and process SUMO itself during maturation from its
precursor (Reverter and Lima, 2006; Shen et al., 2006).
Depending on the modified protein, SUMOylation can act either
as a positive or negative regulator in polyQ expansion disease. In a
Drosophila model of Huntington’s disease (HD), genetic reduction
of SUMO1 was protective, and SUMOylation decreased the
aggregation of the HD exon-1-polyQ protein in a cell model
(Steffan et al., 2004). It has been shown that disruption of
SUMOylation of the polyQ-androgen receptor enhanced its
hormone-dependent transcriptional regulatory activity (Chua
et al., 2015). A role of PML as the SUMO E3 ligase for ataxin-1
was uncovered, and it was shown that ataxin-1 with an expansion of
82Q was subjected to SUMO-dependent polyubiquitination by
RNF4 and subsequent proteasomal degradation (Guo et al., 2014).
We have shown previously that non-expanded ATXN7 and
polyQ-ATXN7 are modified by SUMO on lysine 257, and that
SUMOylation affects mutant ATXN7 aggregation (Janer et al.,
2010). The aims of the present study were to: (1) further understand
the mechanism of mutant ATXN7 SUMOylation and its implication
on protein accumulation; (2) elucidate the physiological role of
mutant ATXN7 modification by SUMO2; and (3) understand
whether a deregulation of the SUMO pathway might contribute to
SCA7 pathogenesis.
RESULTS
ATXN7 is modified by SUMO2 in cells
Modification of proteins with the different SUMO paralogs SUMO1
or SUMO2/3 produces different functional outcomes. Although we
have previously shown that cellular ATXN7 is SUMOylated upon
overexpression of SUMO1 (Janer et al., 2010), it remained unclear
which SUMO paralog is conjugated at endogenous levels. Therefore,
we performed immunoprecipitations using a protocol designed for
the specific enrichment of endogenous SUMO1 and SUMO2/3-
modified proteins from extracts prepared under denaturing conditions
(Barysch et al., 2014) UsingMCF7 cells, a cell line in which ATXN7
is well expressed, antibodies against both SUMO1 and SUMO2/3
could efficiently enrich endogenous modified ATXN7, producing
bands at 120 kDa when probed with anti-ATXN7 antibody (Fig. 1A,
top) and at 90 kDa when probed with anti-RanGAP1 antibody, used
here as a control for anti-SUMO immunoprecipitation (Fig. 1A,
bottom; Fig. S1). We conclude that endogenous ATXN7 can be
conjugated by both SUMO1 and SUMO2/3.
For the polyQ-containing proteins huntingtin and ataxin-1, it has
been shown that SUMO2 modification and subsequent proteasomal
degradation modulates the accumulation of insoluble mutant
protein (Guo et al., 2014; O’Rourke et al., 2013). As our interest
is understanding the mechanism modulating accumulation of
misfolded mutant ATXN7 and, further, given the involvement
of SUMO2 in the degradation of polySUMOylated proteins,
we decided to focus our investigations on the modification of
polyQ-ATXN7 by SUMO2/3.
To determine whether endogenous SUMO2/3 is also conjugated
to the pathogenic mutant ATXN7, we expressed wild-type (10Q) or
mutant (72Q) hemagglutinin (HA)-tagged ATXN7 in HEK293
cells, followed by a denaturing immunoprecipitation using anti-
HA-coupled beads. Mutant 72Q-HA-ATXN7 accumulates in
cells compared with 10Q-HA-ATXN7, as attested by the intensity
of the respective bands, both in input and after denaturing
immunoprecipitation (Fig. 1B, top). Therefore, for a correct
comparison of the SUMOylation levels between 10Q and 72Q-
HA-ATXN7, we adjusted the amount of the 10Q and the 72Q
ATXN7 proteins according to a similar level of unmodified ATXN7
(Fig. 1B, bottom, IB: HA) (Guo et al., 2014). We found both normal
(10Q) and mutant (72Q) ATXN7 conjugated to endogenous
SUMO2/3 (Fig. 1B, bottom, IB: SUMO2/3), migrating at
high-molecular-mass (HMW) levels. These HMW bands were
more intense for mutant (72Q) ATXN7 than for normal (10Q)
ATXN7 and absent in mock-transfected cells. Densitometry
scanning of blots and quantification showed that the SUMO2/3-
modified fraction of mutant ATXN7 was almost 10-fold more
abundant than its wild-type counterpart (Fig. 1B, graph).
To investigate the localization of mutant ATXN7 and SUMO2 in
cell nuclei, we combined immunofluorescence and the proximity
ligation assay (PLA), a technique that permits the detection of
proteins located in close proximity (40 nm or less). Mutant ATXN7-
72Q was expressed either alone or with HA-SUMO2 in HeLa cells.
OverexpressedATXN7-72Q can be detected by immunofluorescence
in intranuclear inclusions (Fig. 1C, b) that appear as irregular dots of
various sizes that are either juxtaposed or colocalized with SUMO2/3-
positive dots that probably represent nuclear bodies. The presence of
red dots in the PLA assay demonstrates that mutant ATXN7 and
endogenous SUMO2/3 are in close contact in the nucleoplasm
(Fig. 1C, g). Interestingly, the PLA signal did not always
colocalize with endogenous SUMO2/3-positive dots visualized by
immunofluorescence, suggesting that mutant ATXN7 interacts with
endogenous SUMO2 also outside of nuclear bodies, in which
SUMO2/3 is normally most concentrated.
However, co-expression of SUMO2 with ATXN7-72Q led to the
complete colocalization between ATXN7 dots (green,
immunofluorescence) and PLA foci (red), suggesting that a high
degree of SUMOylation modified ATXN7 intranuclear localization
(Fig. 1C, n-p). Overexpression of SUMO2 modifies the aspect of
intranuclear accumulated ATXN7-72Q and leads to the formation of
more numerousATXN7-positive small dots.We conclude that mutant
ATXN7 and endogenous or exogenously overexpressed SUMO2 are
in close proximity in the nucleus, and that enhanced expression of
SUMO2 impacts the subnuclear localization of ATXN7.
ATXN7 inclusions colocalize with endogenous SUMO2/3,
PML and ubiquitin
We next investigated whether the interaction between SUMO2/3 and
mutant ATXN7 correlated with aggregation. We overexpressed
polyQ-expanded EGFP-ATXN7-100Q in HeLa cells and determined
the localization of ATXN7 and endogenous SUMO2/3. Different
populations of cells could be distinguished with respect to ATXN7
expression levels by the form or size of the proteinaceous inclusions
in the nucleus and their colocalization with endogenous SUMO2/3.
Cell nuclei with strong ATXN7 expression (23% of the total cells
analyzed) contained large non-homogenous inclusions with little
or no distinct SUMO2/3 staining (13% SUMO2/3-ATXN7
colocalization) (Fig. 2A, b-d). Cells with moderate ATXN7
expression levels (29% of total) presented intermediate-sized, or
smaller, dense mutant ATXN7 inclusions, which contained or are
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juxtaposed to small dot-like SUMO2/3-positive structures (Fig. 2A, f-h;
25% SUMO2/3-ATXN7 colocalization). Finally, cells displaying
lowest expression (48% of total) of ATXN7 contained mostly diffuse
mutant ATXN7, with some concentration in small dots displaying
increased colocalization (45%) with endogenous SUMO2/3 dots
(Fig. 2A, j-l). These data suggest that colocalization between ATXN7
and endogenous SUMO2/3 correlates with the form and size of
the proteinaceous inclusions. Interestingly, the smallest ATXN7 dots
colocalize more often (45%) with endogenous SUMO2/3. Whether
the correlation observed reflects how cells deal with misfolded
mutant ATXN7 cannot be concluded here.
We next investigated whether mutant ATXN7-positive dots that
colocalize with SUMO2/3 correspond to nuclear bodies and
determined the ubiquitination status of ATXN7. We expressed
HA-ATXN7-72Q in HeLa cells and triple-immunofluorescence
staining showed that intranuclear inclusions of mutant ATXN7
colocalized extensively (55±10% of colocalization) with PML
nuclear bodies (Fig. 2B) and widely with SUMO2/3 dots (62±15%
of colocalization). We hypothesized that a SUMO-dependent
ubiquitin ligase could act on mutant ATXN7, as was demonstrated
for ATXN1 (Guo et al., 2014), and checked the ubiquitination status
of mutant ATXN7 inclusions. Indeed, ATXN7-positive intranuclear
Fig. 1. ATXN7 ismodified bySUMO2 in cells. (A)MCF7 cell lysatewas subjected to denaturing immunoprecipitationswith beads coupled tomonoclonal antibodies
against SUMO1, SUMO2 or IgG (control). Top: enriched endogenous SUMO targets were eluted from beads with peptides corresponding to the epitopes of both
SUMO antibodies. Shown are immunoblots against ATXN7 and against the abundant SUMO target RanGAP1 as positive control. SUMO-modified ATXN7 is
boxed (ATXN7-S). The asterisk indicates non-specific band. (B) Both wild-type (10Q) and mutant (72Q) ATXN7 are SUMO2/3 modified. HEK293 cells
expressing HA-ATXN7 with 10Q or 72Q were subjected to denaturing immunoprecipitation (d-IP) using anti-HA antibody-coupled beads (d-IP: HA), followed by
western blotting. Input and d-IP products are revealed with anti-HA tag (top). To compare the level of SUMO2/3 modification, normalization to the unmodified
protein is mandatory: d-IP products with a similar level of unmodified HA-ATXN7-10Q and 72Q were analyzed (IB: HA, bottom). Quantification of the SUMOylated
species is shown (graph). Results are mean±s.d. Statistical analysis was performed using Student’s t-test (**P<0.01; n=3). (C) Interaction between ATXN7-72Q
and SUMO2/3 and their colocalization in HeLa cells determined by proximity ligation assay (PLA, antibodies used are written in red) and immunofluorescence.
Row a-d: overexpressed ATXN7-72Q detected by immunofluorescence appears as irregular dots; some of them are colocalized or juxtaposed (arrows) with
endogenousSUMO2/3. Rowe-h: overexpressedATXN7andendogenousSUMO2/3: the red dots in thePLAassay demonstrate thatmutant ATXN7andendogenous
SUMO2/3 are in close contact. By immunofluorescence (green dots), we detected ATXN7 andSUMO2/3. Rowm-p: co-expression of mutant ATXN7-72Q and SUMO2
led to the complete colocalization between ATXN7 dots (green, immunofluorescence) and PLA foci (red). Arrows in p indicate examples of complete colocalization
between ATXN7 immunofluorescence and the PLA signal. Mouse monoclonal anti-1C1 (ATXN7) and rabbit polyclonal anti-SUMO2/3 antibodies were used. Rows
i-l and q-t: two negative controls for PLA show that no unspecific signal was detected (k, s). Representative confocal images are shown. Scale bars: 5 µm.
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Fig. 2. Mutant ATXN7 aggregation and colocalization with SUMO2/3, PML and ubiquitin. (A) In HeLa cells, overexpressed EGFP-ATXN7-100Q colocalized
with endogenous SUMO2/3 in patterns reflecting the stage of ATXN7 aggregation: a-d, intensely stained, non-homogenous ATXN7-positive inclusions with rough
edges did not colocalize with SUMO2/3; e-h, large ATXN7-positive intermediate-sized inclusions in which the mutant protein is juxtaposed to SUMO2/3 (h, arrows);
i-l, diffuse nuclearATXN7andsmallmutant ATXN7-positive inclusions that colocalizewithSUMO2/3-positive dots (l, arrows). A rabbit polyclonal anti-SUMO2/3antibody
was used. Representative confocal images are shown. Scale bars: 5 µm. The graph on the right shows the percentage of endogenous SUMO2/3 colocalized with
each of the three ATXN7 patterns (see images, left) in n=65 cells from three independent experiments: three configurations were distinguished according to expression
levels, i.e. the fractional area of ATXN7-positive inclusions relative to the nuclear surface of the confocal section. Results are mean±s.e.m. Statistical analysis was
performed using Student’s t-test: *P<0.015, ***P<0.0007. (B) In HeLa cells, overexpressedHA-ATXN7-72Q detected in inclusions colocalizedwith endogenous PML in
nuclear bodies andwithSUMO2/3. TheATXN7-72Q-positive inclusionsalso colocalizedwith ubiquitin andPML.Arrowshighlight the colocalization of ATXN7 inclusions
with the indicated proteins (PML and SUMO2/3, and PML and ubiquitin). Antibodies used: rabbit polyclonal anti-ATXN7, chicken anti-PML, mouse monoclonal anti-
polyubiquitinated proteins FK2, mouse anti-SUMO2/3. Quantification of ATXN7-72Q-positive inclusions with PML, ubiquitin and SUMO2/3 in n=130 cells from n=3
independent experiments. Representative confocal images are shown in A (scale bars: 5 µm) and B (scale bars: 10 µm). (C) HEK293 cells overexpressing mutant
ATXN7-72Qor itsSUMO-deficient KRor 7KRmutantswere analyzed in the presence of endogenous oroverexpressedSUMO2.Shownare immunoblots of theNP-40-
soluble fraction (NS) analyzed with anti-ATXN7 and anti-FLAG to detect expressed SUMO2. The proteasome was inhibited by epoxomicin (1 µM) treatment for 16 h.
Asterisks indicate SUMO2-modified ATXN7-72Q. Quantification of the ratio of soluble ATXN7/tubulin, compared with the condition in lane 1 (DMSO, top graph) or
lane 7 (epoxomicin, bottom graph). Data are mean±s.d. of n=3 independent experiments. Statistical analysis was performed using Student’s t-test (**P<0.01).
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dots colocalized to a high extent (68±8%) with ubiquitin (Fig. 2B).
This demonstrates that mutant ATXN7 concentrates in dots that
colocalize with PML bodies and SUMO2/3. In addition, mutant
ATXN7 intranuclear inclusions colocalize with ubiquitin, suggestive
of a possible link with degradation.
SUMO2modification ofATXN7promotesprotein degradation
Poly-SUMOylation by SUMO2 is known to be related to protein
degradation (reviewed in Sriramachandran and Dohmen, 2014).
Moreover, we have shown previously that clastosomes, which are
PML bodies enriched in proteasomal subunits, degrade mutant
ATXN7 (Janer et al., 2006). In order to investigate SUMO2 and a
potential involvement of the proteasome, we compared the
expression of mutant ATXN7-72Q and its SUMOylation-deficient
variant K257R (KR) (Janer et al., 2010), as well as variant 7KRwith
seven lysines mutated into arginine at positions 117, 223, 226, 257,
287, 321 and 858, in HEK293 cells.We analyzed the NP-40-soluble
(NS) fraction by western blotting.
Without SUMO2 co-expression, SUMOylated ATXN7-72Q was
undetectable on direct immunoblots in the NS fraction (Fig. 2C,
lane 1). Co-expression of SUMO2 resulted in weakly detectable
levels of SUMOylated polyQ-ATXN7 (asterisks, lane 4). Finally,
proteasome inhibition with epoxomicin led to a striking stabilization
of the SUMOylated ATXN7-72Q (asterisks, lane 9). As expected, the
SUMOylation-deficient variants KR and 7KR were not modified by
SUMO2. In addition, the band corresponding to unmodified ATXN7
was significantly reduced (0.44±0.05) in the presence of SUMO2 co-
expression (Fig. 2C, lane 4, compared with lane 1), an effect reversed
by epoxomicin treatment. Taken together, these results suggest that
SUMO2 modification contributes to ATXN7-72Q degradation, most
probably via the proteasome.
The SUMO-dependent ubiquitin ligase RNF4 mediates
ATXN7 degradation via the proteasome
Proteasomal degradation of poly-SUMOylated proteins has been
shown to involve the action of the SUMO-dependent ubiquitin
ligase RNF4 (Lallemand-Breitenbach et al., 2008; Rojas-Fernandez
et al., 2014; Tatham et al., 2008; Ulrich, 2008). To test this idea, we
expressed ATXN7-72Q in combination with wild-type RNF4 and
RNF4 mutated in the SUMO-interacting motifs (SIMs) (to prevent
binding to SUMO2 chains) or in the RING domain (to abolish
ubiquitin E3 ligase activity) (Fig. 3A; Fig. S2). This was done with
or without overexpression of SUMO2 in order not to limit SUMO2
levels. Co-expression of wild-type RNF4 with SUMO2
significantly decreased (0.52±0.08, lane 4) the level of soluble
mutant ATXN7 compared with the expression of ATXN7-72Q only
(0.93±0.17, lane 1). Expression of the RNF4 SIM mutant did not
significantly influence the level of soluble ATXN7 (0.71±0.06, lane
6), but expression of the RNF4 RINGmutant led to accumulation of
SUMOylated ATXN7, an effect that was potentiated by co-
transfection of SUMO2 (with decreased unmodified ATXN7,
0.61±0.09, lane 8). Thus, the RNF4 RING mutant appeared to
behave as a dominant negative. This highly SUMOylated ATXN7
exhibits greater solubility, as decreased levels of sodium dodecyl
sulfate (SDS)-resistant aggregates (SR) were detected in these cells
by the filter retardation assay (Fig. 3A, bottom). This assay is
complementary to western blotting as it detects aggregated species
that do not enter the resolving gel because they are trapped in the
stacking gel. Moreover, in the SR fraction, cells co-expressing
SUMO2 and wild-type RNF4 contain fewer SDS-resistant
aggregates than cells co-expressing only SUMO2. Together, our
results on soluble and insoluble mutant ATXN7 suggest a role for
RNF4 in misfolded mutant ATXN7 degradation. Consistent
with these observations, silencing of endogenous RNF4 by short
interfering RNA (siRNA) led to an increase in SUMOylated
ATXN7 species, both after denaturing immunoprecipitation
(Fig. 3B, top, IB: SUMO2) and in direct immunoblotting (see
asterisks in Fig. 3B, bottom, IB: ATXN7 and IB: HA).
Analysis by three-color immunofluorescence (Fig. 3C) showed
mutant ATXN7, RNF4 and endogenous SUMO2/3 to colocalize in
numerous subnuclear foci. Although the RNF4 RING mutant
(dHC) still colocalized with a subset of foci containing SUMO2/3
and ATXN7, the RNF4 SIM mutant did not, most probably due to
its inability to recognize and bind SUMO2 chains (Fig. 3C). Given
our previous demonstration that mutant ATXN7 is recruited into
nuclear PML clastosomes, where it is degraded by proteasome
components (Janer et al., 2006), we thus asked whether the
modification by SUMO2 and the recognition by RNF4 contribute
to the recruitment of mutant ATXN7 into PML bodies.
Immunofluorescence staining of mutant ATXN7 showed indeed
its colocalization with RNF4 protein within PML bodies (Fig. 3D).
Together, our results suggest that the SUMO2-mediated
degradation of mutant ATXN7 involves the action of RNF4 and
thus provides a molecular explanation (Gärtner and Muller, 2014)
for the previously described pathway for ATXN7 degradation in
PML clastosomes (Janer et al., 2006).
To investigate whether the RNF4-induced decrease in mutant
ATXN7 was due to proteasome-dependent degradation, we inhibited
the proteasome by epoxomicin in HEK293 cells co-expressing
ATXN7-72Q and wild-type RNF4 with or without overexpression of
SUMO2, followed by denaturing ATXN7 immunoprecipitation. In
order to determine the extent to which ATXN7 is SUMO or ubiquitin
modified, samples need to be normalized with respect to the levels of
unmodified ATXN7 (see explanation provided with Fig. 1B). Results
are presented before and after normalization. Consistent with our
previous results (Fig. 2C), proteasome inhibition by epoxomicin led
to a strong accumulation of SUMO2-conjugated ATXN7 [Fig. 4A,
d-IP: HA (ATXN7); IB: SUMO2, lanes 5-8] by a factor of 1.95
(Fig. 4B, top, lane 5). In dimethyl sulfoxide (DMSO) conditions,
overexpression of RNF4 leads to a significant decrease in
SUMO2(n)-modified ATXN7 (Fig. 4B, top; 0.32±0.15, lane 3
compared with lane 1), in agreement with our hypothesis on the role
of RNF4 in ATXN7 degradation. Additionally, following denaturing
immunoprecipiation, samples were analyzed for their polyubiquitin
content (IB: Ubi). In control (DMSO) samples, RFN4 expression
enhances almost six times, from 0.1 to 0.62, the polyubiquitin signal
in normal condition (Fig. 4B, bottom, compare lanes 3-4 with lane 1).
After epoxomicin treatment, there is a strong (1.910±0.480, lane 5)
accumulation of Ubi-conjugated ATXN7, an effect that is highly
triggered by RNF4 (3.72±0.70, lane 7; 3.43±0.50, lane 8) (Fig. 4B,
bottom), suggesting that RNF4 expression strongly enhances the
polyubiquitination of SUMO2-modified ATXN7. Furthermore, in
DMSO samples, RNF4 co-expressed with SUMO2 leads to a strong
decrease in SUMO-modified ATXN7, compared with SUMO2
expression only (Fig. 4B, top, lane 4 compared with lane 2), an effect
that is reversed in the presence of epoxomicin. Altogether, these
results strongly suggest the involvement of RNF4 in the clearance of
poly-SUMO2 modified mutant ATXN7 via the proteasome.
Endogenous RNF4 colocalizes with ATXN7 and SUMO2
We then compared, by immunofluorescence, the cellular distribution
of endogenous and exogenous RNF4 in cells expressing EGFP-
ATXN7-100Q. Exogenous wild-type RNF4 was both diffuse and
colocalized with nuclear EGFP-ATXN7-100Q inclusions (Fig. 3C),
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whereas endogenous RNF4was detected only within the larger-sized
EGFP-ATXN7-100Q inclusions in ATXN7-overexpressing cells
(Fig. 4C, g). Following proteasome inhibition, endogenous RNF4
became enriched around a single large EGFP-ATXN7-100Q
inclusion in a subset of cells (Fig. 4C, o). A similar pattern was
observed for SUMO2/3 in epoxomicin-treated cells (Fig. 4C, k).
These findings are consistent with a possible role of RNF4 in
mediating the SUMO-dependent degradation of ATXN7.
Fig. 3. SUMO-dependent ubiquitin ligase RNF4 mediates ATXN7 degradation. (A) HeLa cells overexpressing ATXN7-72Q, SUMO2 and RNF4 [wild type (WT)
or mutated in the SIM (dSIM) or RING domain (dHC)]: immunoblot analysis of the NP-40-soluble fraction (NS). Filter retardation assay of the SDS-resistant (SR)
fraction (n=4). Quantification of the ratio of soluble ATXN7/tubulin expressed as mean±s.d. (n=3). Statistical analysis was performed using Student’s t-test: *P<0.05
(lanes 4 and 8 compared with lane 1). (B) Levels of SUMOylated HA-ATXN7-72Q in cells treated with a control siRNA (CTRL) or an siRNA targeting RNF4 (n=2).
Normalization: d-IP products with similar levels of unmodified ATXN7 protein were compared (d-IP, IB: HA). WCL, whole-cell lysate. ATXN7 was detected with
two different antibodies (polyclonal anti-ATXN7 and monoclonal anti-HA) confirming that the HMW species (indicated by asterisks) are a modified form of ATXN7.
(C) HeLacells co-expressingEGFP-ATXN7-100QandRNF4 [wild type (WT)ormutated in theSIM (dSIM) orRINGdomain (dHC)]: immunofluorescence showsRNF4
relative to SUMO2-positive ATXN7 intranuclear inclusions. RNF4 WT perfectly colocalized with mutant ATXN7 and SUMO2 (see arrows and higher magnification
images); the RING mutant still colocalized (arrows) but the RNF4 SIM mutant did not and displayed only diffuse nuclear signal. (D) Colocalization between
overexpressed mutant ATXN7, RNF4 and endogenous PML (arrows) in the nucleus of HeLa cells. Representative confocal images are shown. Scale bars: 5 μm.
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Investigation of the SUMO pathway in SCA7 knock-in mice
To determine whether our previous findings could be transposed to
an in vivo pathological context, we next investigated ATXN7 and
SUMO2/3 colocalization in Atxn7100Q/5Q mice, a polyQ-ATXN7
knock-in mouse line that develops retinal degeneration, weight
loss, kyphosis, ataxia, ptosis, tremor and gradual loss of mobility
(Chen et al., 2012). Owing to instability of the CAG repeat, which
leads to an expansion of 120Q on one allele, the lifespan of
Atxn7100Q/5Q mice in our colony is 13-14 months, instead of
18 months (Chen et al., 2012). We analyzed cerebellum and retina,
Fig. 4. See next page for legend.
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the most affected tissues in SCA7, at 12 months, when the mice are
severely affected.
In the cerebellum of Atxn7100Q/5Qmice, ATXN7 is localized in the
nucleus of Purkinje cells, where it mostly accumulates in a single
large inclusion. SUMO2/3 colocalized with mutant ATXN7 in the
inclusion (Fig. 5A). Retinal neurons are distributed in three nuclei
layers: (1) the cell bodies of rod and cone photoreceptors that are in the
outer nuclear layer (ONL); (2) the nuclei of bipolar, horizontal and
amacrine cells that are in the inner nuclear layer (INL); and (3) nuclei
of the ganglion cell layer (GCL), the closest to the optic nerve. Mutant
ATXN7 accumulated in nuclear inclusions in Atxn7100Q/5Q mice
retina. The inclusions’ sizes differed depending on the retinal layer in
which they were located: the larger inclusions were found in the GCL
and colocalized perfectly with SUMO2 (Fig. 5A, f-h). By contrast, in
the INL and ONL, where ATXN7-positive inclusions were smaller,
SUMO2 staining was intense in INL nuclei but colocalization was
only partial (Fig. 5A, j-l). Finally, in the ONL, SUMO2 staining was
weak, mostly cytoplasmic and did not colocalizewith ATXN7. Taken
together, these results show significant co-occurrence of ATXN7 and
SUMO2/3 in some (GCL), but not all (ONL), cells affected by SCA7
pathology in the Atxn7100Q/5Q mouse model. There are cell-type-
specific differences that might explain the differences in the degree of
colocalization between inclusions and SUMO2.
We then compared severely affected Atxn7100Q/5Qmice and wild-
type littermates at 12 months of age, for their SUMO2 and ATXN7
content in affected brain regions, such as the cerebellum and
brainstem, as well as in the less-affected cortex. Normal ATXN7
(5Q) is detected as a band around 97 kDa, whereas mutant ATXN7
in Atxn7100Q/5Q mice is SDS insoluble and detected in the stacking
gel; its accumulation is more pronounced in the cerebellum
(Fig. 5B, a; insoluble ATXN7/tubulin ratio of 1.0±0.23) than in
cortex (ratio of 0.38±0.13). Additionally the level of soluble
ATXN7 in the cerebellum was much higher (1.72±0.22) in
Atxn7100Q/5Q mice than in their wild-type littermates (Fig. 5B, c).
Free SUMO2 is detected at 17 kDa (Fig. 5B, IB: SUMO2, free S2),
whereas polySUMOylated proteins migrate as HMW species, up to
more than 250 kDa [see S2(n)]. In wild-type mice, we quantified
polySUMO2/3 species, whichwere highly enriched in the cerebellum
(ratio of SUMO2/tubulin set at 1.0) compared with cortex (ratio of
0.45±0.12) and brainstem (ratio of 0.34±0.09) (Fig. 5B, b). A similar
pattern was observed in Atxn7100Q/5Q mice. We next compared the
polySUMO2/3 levels in the cerebellum between wild-type and
Atxn7100Q/5Q mice and determined that SCA7 mice contain
1.58±0.23 times more SUMO2(n)/tubulin than the wild-type
littermates. This suggested that, in severely affected mice, there is
an accumulation of polySUMO2/3 species in the cerebellum
compared with control littermates. This difference was not detected
in the cortex, when comparing wild-type with Atxn7100Q/5Q mice,
suggestive of a tissue- and disease-specific SUMO2/3 response.
Whether the ATXN7 aggregates detected on western blots sequester
SUMO2/3 and correspond to colocalized ATXN7 and SUMO2-
positive nuclear inclusions (Fig. 5A) cannot be concluded here.
We previously showed that interferon (IFN)-beta stimulated the
formation of PML clastosomes in vivo, a potential therapeutic approach
for SCA7 (Chort et al., 2013). IFN-beta treatment of Sca7266Q/5Qmice
reduced neuronal intranuclear inclusions composed of insoluble
mutant ATXN7, in parallel to increased PML protein expression in
nuclear bodies (Chort et al., 2013). By western blot analysis of IFN-
beta-treated Sca7266Q/5Q mice (annotated in Fig. 5C as Atxn7266Q/5Q),
we detected also an increase in PML levels (factor of 3.2±0.42) and a
decrease in soluble ATXN7 (by 60%) (Fig. 5C) compared with levels
in murine serum albumin (MSA)-treated mice. Importantly, IFN-beta
improved the locomotion of Sca7266Q/5Q mice, demonstrating a
therapeutic effect. It was demonstrated that IFN-alpha and -gamma
dramatically increase general SUMO1 and SUMO2/3 levels, in vitro as
well as in vivo, through a microRNA-based mechanism (Sahin et al.,
2014): this result prompted us to analyze the SUMO2 levels in
Sca7266Q/5Q knock-in mice treated with IFN-beta compared with
MSA-treated littermates. Interestingly, we detected an important
increase (factor of 2.55±0.25) in the ratio of polySUMO2/tubulin
when comparing IFN-beta-treated withMSA-treated Sca7266Q/5Qmice
(Fig. 5C). Thus, we suggest that, although IFN acts through many
mechanisms, the degradation of mutant ATXN7 that we observed
might involve the polySUMO2-modification of ATXN7.
We next analyzed the expression of SUMO-pathway-related
transcripts in the cerebellum of wild-type Atxn75Q/5Q and Atxn7100Q/5Q
mice at 6 and 12 months of age by quantitative reverse transcription
polymerase chain reaction (RT-PCR). The relative levels of mRNA
were standardized to Rplp0 ribosomal RNA, and to beta-
2microglobulin (B2m) as non-variant RNA species, according to
Boda et al. (2009). At 6 months (before the development of motor
symptoms), we did not observe statistically significant modifications
in mRNA expression in the cerebella of Atxn7100Q/5Qmice compared
with wild-type littermates, except for Senp2 (Fig. 6A). At 12 months,
a statistically significant reduction in Sumo1 (P=0.0048), Pias2
(P=0.028), Pias4 (P=0.024), Senp2 (P=0.0079) and Senp6
(P=0.0021) expression was detected in Atxn7100Q/5Q mice
compared with wild-type littermates (Fig. 6A). Sumo2 expression
was decreased at 12 months in Atxn7100Q/5Q mice compared with
wild-type littermates, but this difference was not statistically
significant. We also compared the differences in expression at 6
and 12 months of age in the Atxn7100Q/5Q mice and found a
statistically significant difference in the expression of Sumo1
(P=0.0002), Pias4 (P=0.007), Sumo2 (P=0.035), Senp2 (P=0.038),
Senp3 (P=0.027) and Senp6 (P=0.023), indicating that when disease
worsens in mice, the SUMO pathway is downregulated.
We also analyzed mRNA expression of SUMOylation enzymes
in SCA7266Q/5Q knock-in mice treated with IFN-beta compared with
Fig. 4. Proteasome inhibition abolishes mutant ATXN7 degradation via
RNF4. (A) HEK293 cells overexpressing ATXN7-72Q, SUMO2 and RNF4
were treated with DMSO (control) or epoxomicin (1 µM for 16 h). Denaturing
immunoprecipitation (d-IP) samples with similar levels of unmodified
ATXN7-72Q were analyzed, as normalization is required for a comparison of
modified ATXN7 levels. d-IP products, before normalization (top panel, lowand
high exposures; asterisks indicate poly-SUMO2 modified HA-ATXN7-72Q),
and input in whole-cell lysate (WCL; bottom panel; asterisk indicates
SUMO2-modified ATXN7) are shown. d-IP products after normalization are
shown in the middle panel (IB: SUMO2, IB: Ubi, IB: HA). Co-expression of
RNF4 and SUMO2 decreased SUMO2-modified ATXN7. Epoxomicin
treatment led to SUMO2- (IB: SUMO2) and ubiquitin- (IB: Ubi) modified ATXN7
accumulation. RNF4 promoted the ubiquitination of modified ATXN7. (B) Top:
quantification of the ratio of polySUMOylated ATXN7-S2(n)/unmodified
HA-ATXN7-72Q in DMSO (lanes 1-4) and epoxomicin conditions (lanes 5-8).
Bottom: quantification of the ratio of polyubiquitinated ATXN7-Ubi(n)/
unmodified HA-ATXN7-72Q. Data are mean±s.d. (n=3). Statistical analysis
was performed using Student’s t-test: *P<0.05, **P<0.01. (C) Colocalization
of expressed EGFP-mutant ATXN7 with endogenous SUMO2/3 and
endogenous RNF4 in HeLa cells in control (DMSO, a-h) or epoxomicin (i-p)
conditions. Endogenous RNF4 was detected in a subset of ATXN7-positive
inclusions in the control condition ( f, g, see arrows and higher magnification
images), but following epoxomicin treatment became enriched around one
large EGFP-ATXN7-100Q inclusion (o, arrow). SUMO2/3 shows a similar
enrichment around an ATXN7 inclusion when proteasomal degradation is
blocked (k; the arrow points to endogenous SUMO2/3 surrounding one large
EGFP-ATXN7-100Q inclusion in epoxomicin-treated cells). Representative
confocal images are shown. Scale bars: 5 μm.
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MSA-treated littermates. The results obtained were in line with our
data on SUMO2/3 from western blot analyses: IFN-beta
significantly increased the expression of Sumo1 (P=0.0158),
Sumo2 (P=0.0097) and SUMO-related enzymes such as Pias1
(P=0.0009), Pias3 (P=0.0183) and Pias4 (P=0.0133) in these mice
(Fig. 6B), thus supporting the therapeutic benefit of IFN-beta
treatment and confirming the importance of SUMOylation pathway
in SCA7 pathology.
Fig. 5. In vivo investigation of mutant ATXN7, SUMO2/3 and PML protein expression and colocalization in two SCA7 KI mouse models.
(A) Cerebellum (a-d) of a 12-month-oldAtxn7100Q/5Qmousewas labeled with a polyclonal anti-ATXN7 antibody and amonoclonal anti-SUMO2 antibody. SUMO2
(dot in c, see arrow) colocalized strongly (arrow in d) with anATXN7-positive intranuclear inclusion in a Purkinje cell (92.8±4.7%of colocalization; n=200Purkinje cells
counted in lobes V and VI from n=2 Atxn7100Q/5Q mice). GCL, granular cell layer; ML, molecular layer; PCL, Purkinje cell layer. Retina (e-l) of a 12-month-old
Atxn7100Q/5Qmouse: SUMO2 protein (g, k, arrows indicate dots where SUMO2 is concentrated) colocalized perfectly with mutant ATXN7 inclusions in the ganglion
cell layer (h, arrows) and in a subset of cells in the INL (l, arrows). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Representative confocal
images are shown. Scale bars: 10 μm. (B) Western blot analysis of brains from 12-month-old Atxn7100Q/5Q mice and their wild-type littermates. Levels of ATXN7
and poly-SUMO2 proteins are highly increased in the cerebellum of Atxn7100Q/5Q mice compared with wild-type littermates. Quantification of soluble ATXN7/tubulin
and SUMO2(n)/tubulin is shown (graphs c and d; comparison of Atxn7100Q/5Q and wild-type mice). In Atxn7100Q/5Q mice, mutant insoluble ATXN7 accumulates
more in the cerebellum (1.00±0.23) than in cortex (0.38±0.13) (graph a). In wild-type littermates, poly-SUMO2 protein is more abundant in the cerebellum than in
the cortex, rest of the brain and brainstem (graph b). Data are mean±s.d. from n=3 independent analyses. Statistical analysis was performed using Student’s t-test:
*P<0.05; **P<0.01. (C) Western blot analysis of cerebellar extracts from IFN-beta-treated Atxn7266Q/5Q mice compared with MSA-treated mice. An important
increase (factor of 2.55±0.25) in the ratio of polySUMO2/tubulin was detected when comparing IFN-beta-treated with MSA-treated Atxn7266Q/5Q mice. In
agreement with our previously published results (Chort et al., 2013), an increase in PML levels (factor of 3.2±0.42) and a decrease in soluble ATXN7 (by 60%)
are observed in Atxn7266Q/5Q mice after IFN-beta treatment compared with MSA treatment. Data are mean±s.d. from n=3 independent analyses. Statistical
analysis was performed using Student’s t-test: *P<0.05; **P<0.01.
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Accumulation of SUMO pathway components in the
cerebellum of SCA7 patients
Because neuronal death is particularly important in the Purkinje cell
layer of SCA7 patients, we investigated SUMOylation of ATXN7 in
the cerebellum of postmortem brains from two patients and a
control. In the control brain, ATXN7 staining was diffuse in nuclei
and the cytoplasm, with a stronger signal along the nuclear
membrane (Fig. 7A, a). In the SCA7 patients, Purkinje cell bodies
were shrunken and ATXN7 strongly accumulated in both the nuclei
and cytoplasm (Fig. 7A, b, c). SUMO1 staining, which was granular
and diffuse, increased in Purkinje cell nuclei and cytoplasm in
the SCA7 brains, compared with the control brain, in which
staining, mostly cytoplasmic, was also diffuse (Fig. 7A, d compared
with e, f ). SUMO2 was faintly stained in nuclei of Purkinje cells in
Fig. 6. Expression of SUMO pathway-related genes in two SCA7 knock-in mice models. (A) Quantitative RT-PCR analysis of SUMO pathway enzymes in
cerebella from 6- and 12-month-old Atxn7100Q/5Q mice and wild-type littermates. SUMO enzymes were differentially expressed in 6-month-old Atxn7100Q/5Q
versus wild-type mice; a statistically significant decrease was observed only for Senp2 (P=0.047). At 12 months, a statistically significant decrease in
Sumo1 (P=0.0048), Pias2 (P=0.028), Pias4 (P=0.024), Senp2 (P=0.0079) and Senp6 (P=0.0021) was observed. Comparison between 6-month-old and 12-
month-old Atxn7100Q/5Qmice confirmed the significant decrease in Sumo1 (P=0.0002), Sumo2 (P=0.035), Pias4 (P=0.007), Senp2 (P=0.038), Senp3 (P=0.027)
and Senp6 (P=0.023) mRNA expression. Samples were analyzed in triplicate and normalized to mouse Rplp0 and B2m. (B) Quantitative RT-PCR of
SUMO mRNAs from cerebella of 12 week-old SCA7266Q/5Q knock-in mice, injected intraperitoneally with either mouse IFN-beta or MSA (control). SUMO
enzymes were significantly increased in IFN-beta-treated mice versus MSA controls: Sumo1 (P=0.0158), Sumo2 (P=0.0097), Pias1 (P=0.0009), Pias3
(P=0.0183), Pias4 (P=0.0133). Samples were analyzed in triplicate and normalized to mouse Rplp0 ribosomal gene. One-way ANOVAwas applied for statistical
analysis. Data are mean±s.d. (n=5 in each group). *P<0.05; **P<0.005; ***P<0.0005.
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the control brain, whereas in the two SCA7 cases, the shrunken
Purkinje cell soma showed accumulation of SUMO2 in darker spots
and the nuclei appeared condensed and strongly stained (Fig. 7A, g
compared with h, i). RNF4 staining in the control brain was granular
and diffuse, and mostly cytoplasmic in Purkinje cells (Fig. 7A, j ). In
the SCA7 brains, RNF4 staining was more intense than in the
control brain; in addition, the nuclei of Purkinje cells were strongly
labeled (Fig. 7A k, l ). The accumulation of RNF4 in SCA7 Purkinje
Fig. 7. SUMO proteins accumulate abnormally in the cerebellum of two SCA7 patients.Model proposed for mutant ATXN7 degradation via the proteasome.
(A) Postmortem cerebellar tissues from two SCA7 patients with morphologically and genetically confirmed SCA7 (57 and 10 years old at death; with 47 CAG
repeats and 85 CAG repeats on the mutant allele in peripheral blood, respectively) and a control (52 year-old) with no neurological disease were analyzed by
immunohistochemistry; representative images are shown. In the cerebellum of the SCA7 patients, ATXN7 accumulated strongly in nuclei and cytoplasm of
the few surviving Purkinje cells (b, c). SUMO1 (e, f ) and SUMO2/3 (h, i) immunoreactivity increased strongly in the nucleus and, to a lesser extent, in the
cytoplasm of Purkinje cells in the SCA7 patients. RNF4 accumulated in the SCA7 patients, both in the cytoplasm and in the nucleus of the Purkinje cells (k, l ).
We analyzed n=20 Purkinje cells for each patient: cells in which nuclei were not visible were not taken into account. GCL, granular cell layer; ML, molecular
layer; PCL, Purkinje cell layer. Scale bars: 20 μm. (B) Model for mutant ATXN7 degradation via the proteasome. We propose this model, which summarizes
data from this study and our previously published results on polyQ-ATXN7 degradation by PML clastosomes and their stimulation by IFN-beta treatment
(Janer et al., 2006; Chort et al., 2013). First, mutant ATXN7 is modified by SUMO2 by addition of poly-SUMO2/3 chains. This modification promotes the
recruitment of ATXN7 to PML clastosomes, where it is ubiquitinated by the SUMO-dependent ubiquitin ligase RNF4 for its final degradation by the proteasome.
Treatment with IFN-beta enhances clastosome formation and increases SUMO pathway enzymes, promoting further poly-SUMOylation by SUMO2/3 of
polyQ-expanded ATXN7, which finally leads to its enhanced clearance.
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cells paralleled SUMO2 accumulation in the nucleus, suggesting
deregulation of this pathway during the disease.
DISCUSSION
Protein misfolding is a major dysfunction in polyglutamine diseases.
The way neurons handle protein aggregates, either by refolding the
proteins with molecular chaperones or eliminating them once formed,
determines cell survival (Ross and Poirier, 2005).
We previously showed that SUMOylation reduced the toxicity and
aggregation of exogenous mutant ATXN7 (Janer et al., 2010), but the
question remained whether endogenous ATXN7 in proliferating cells
is SUMO modified in physiological conditions. Here, we show, for
the first time, that in unstressed cells, endogenous ATXN7 can be
SUMOylated by SUMO1 and especially SUMO2/3. Interestingly,
this is in agreement with SUMOylation of the yeast homolog of
ATXN7, Sgf73, that was detected in a global proteomics analysis of
SUMOylation (Wohlschlegel et al., 2004).
We also previously demonstrated the specificity of PML isoform
IV and the role of clastosomes, specialized nuclear bodies enriched
in proteasomes, in the degradation of mutant ATXN7 (Janer et al.,
2006). In this study, we investigated the SUMO pathway and showed
a colocalization of mutant ATXN7 and RNF4 within PML-positive
nuclear bodies. Moreover, endogenous RNF4 was found
accumulated around ATXN7 nuclear inclusions. We previously co-
immunoprecipitated PML IV andmutant ATXN7 (Janer et al., 2006),
which is also in agreement with the colocalization between mutant
ATXN7 inclusions and PML observed in this study. Taken together,
these data suggest that RFN4 is involved in the degradation of mutant
ATXN7within clastosomes. Indeed, our results are consistent with an
interaction taking place within PML bodies and particularly in
clastosomes, where proteasomal degradation follows the
polyubiquitination of mutant ATXN7 by RNF4: a potential model
is presented in Fig. 7B. RNF4-mediated protein degradation was first
described for SUMO-modified PML degradation induced by arsenic
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). The
colocalization between endogenous and expressed RNF4 (SNURF)
and PML, along with its interaction in a complex being facilitated by
SUMO1, was first shown by Häkli et al. (2005). Another
transcription factor, Nrf2, which is degraded in the cytoplasm via
Cul3/RING box1 E3 ubiquitin ligase, is also transferred to PML
bodies when SUMOylated (Malloy et al., 2013). Overexpression of
RNF4 decreased the levels of Nrf2 in a PML-enriched cell fraction,
another example of how transcription factors can be degraded via the
proteasome in both the cytoplasm and the nucleus (Malloy et al.,
2013). We show here that SUMOylated mutant ATXN7 is degraded
by RNF4; this pathway mirrors that described in a study on SCA1, in
which mutant ataxin-1 is modified by SUMO2 and targeted for
nuclear degradation via RNF4 (Guo et al., 2014).
To summarize, we illustrated in Fig. 7B a possible mechanism for
the clearance of mutant ATXN7: SUMO2 is added as poly-SUMO
chains to its substrate, polyQ-ATXN7; this modification leads to the
recruitment of the SUMO-targeted ubiquitin ligase RNF4 and to
subsequent ubiquitination and proteasomal degradation of
misfolded ATXN7.
The SUMO2/3 conjugation pathway is known to be upregulated
by several protein-damaging events and is stimulated in a stress-
dependent manner (Saitoh and Hinchey, 2000); for example, by
nuclear accumulation of misfolded proteins. To study a correlation
between SUMO2/3 and stress induced by ATXN7 aggregates, we
investigated the endogenous SUMO2 protein expression both in
vitro (Fig. 2A,B) and in vivo (Fig. 5). In Atxn7100Q/5Qmice, SUMO2
relocalized to ATXN7 intranuclear neuronal inclusions in cerebellar
Purkinje cells and in the retinal ganglion cells, where SUMO2
expression was particularly intense. The GCL, as well as
photoreceptors, were described to be degenerated in a SCA7
patient after autopsy (Gouw et al., 1994), owing to progressive
accumulation of ATXN7 over time. Thus, SUMO2 colocalization
with mutant ATXN7 may be linked to disease progression.
The mechanism proposed here, by which SUMO2 regulates the
clearance of misfolded mutant ATXN7, makes this pathway
particularly relevant to the SCA7 disease. This finding is consistent
with the SUMO2/3modification of huntingtin inHD, as SUMO2/3 is
involved in the accumulation of insoluble mutant huntingtin
(O’Rourke et al., 2013). Relocalization of SUMO2 into
intranuclear neuronal inclusions suggests that chronic expression of
polyQ-expanded ATXN7 produces a misfolded protein recognized
by the SUMOpathway. Nevertheless, this response is not sufficient to
cope with the accumulation of insoluble species, reflecting ongoing
pathogenesis. To better understand SCA7 pathophysiology, we
looked for evidence of a SUMOylation deregulation in vivo in the
Atxn7100/5Q mouse model. Quantification of mRNA showed a
decrease in the transcription of key genes – such as Sumo1, Pias2,
Pias4, Senp2 and Senp6 – at 12 months, and comparison of gene
expression between 6 and 12 months inAtxn7100/5Qmice showed that
deregulation was stronger, especially for Sumo1, Sumo2, Pias4 and
Senp2, Senp3 and Senp6, as the disease worsened. This
downregulation of Senp2, Senp3 and Senp6, which has paradoxical
effects on SUMOylation, being involved in both the maturation of
SUMO peptides as well as in de-SUMOylation, could also contribute
to dysregulation of SUMOylation, particularly at later stages of the
disease. Quantification of poly-SUMO2/3 proteins in the cerebellum
of Atxn7100/5Qmice showed an increase in expression levels of∼50%
compared with their wild-type littermates at 12 months of age. This
reveals a stabilization and longer half-life of SUMO2/3-modified
proteins when the disease progresses that might be related to less-
efficient proteasomal degradation. We suggest that SUMOylation
contributes to the degradation of mutant ATXN7 via active
proteasomes in young mice, but that degradation is compromised in
aged mice, thus ATXN7 inclusions increase over time. It is well
documented that proteasome activity declines during aging, and
proteasomal dysfunction is associated with late-onset disorders, such
as Alzheimer’s disease, Parkinson’s disease or HD (Saez and
Vilchez, 2014).
SUMOylation was also deregulated in the R6/2 mouse model of
HD: both Sumo1 and Sumo2 mRNA increased in the striatum at a
late stage of the disease; the same pattern was observed in the
mRNA expression of enzymes (Senp1, Senp6, Pias3 and Pias4)
involved in this pathway (O’Rourke et al., 2013).
Target specificity for SUMOylation is provided by the SUMO E3
ligases. Comparison of mRNA levels in Atxn7100Q/5Qmice and wild-
type littermates showed that Pias2 and Pias4mRNA expression was
significantly reduced at the end of their life (12 months). Moreover,
in our SCA7 cell model of overexpression, we observed that PIAS
proteins (especially PIAS4), were implicated in the SUMOylation of
ATXN7 (data not shown), suggesting potential target specificity.
We have shown that SUMO1 and SUMO2 colocalized with
ATXN7 in the cortex of SCA7 patients (Janer et al., 2010) and in the
cerebellum and retina of Atxn7100Q/5Q mice (this study). SUMO
proteins and RNF4 were found to accumulate in human SCA7
cerebellar Purkinje cells, suggesting a stabilization of SUMOproteins
along disease progression. The increase in cytoplasmic SUMO1 was
already shown in other neurodegenerative diseases, such as
multiple system atrophy (Pountney et al., 2005). Fluorescence
immunohistochemistry showed that SUMO1 subdomains were
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frequent within and around inclusion bodies and colocalized with a
lysosomal marker, cathepsin-D, in affected brain regions. This
suggests that SUMO1 plays a role in lysosome function (Wong et al.,
2013) and might explain the increase in cytoplasmic SUMO1 in
Purkinje cells in a SCA7 brain. We have shown that the autophagy-
lysosomal degradation pathway contributes to SCA7 (Alves et al.,
2014). SUMO1 and the autophagy-lysosome pathway might
therefore interact or intervene successively in SCA7 if the SUMO
pathway and proteasome cannot handle the amount of misfolded
accumulated proteins in the nucleus: this mechanism has been
proposed for huntingtin degradation as well (Thompson et al., 2009).
There is in vivo evidence that SCA1 and huntingtin mutations affect
SUMOylation. In HD brains, SUMO2-modified HMW species were
detected, as well as huntingtin-positive species migrating at the same
level, strongly suggesting that huntingtin modification by SUMO2 is
active in HD (O’Rourke et al., 2013). Similarly, in Atxn7100/5Q mice
cerebella, we detected SUMO-2/3 HMW species andmutant ATXN7
in the stacking gel. Our results confirm the importance of the SUMO2
pathway and RNF4 in SCA7 and indicate that proteins involved in
the SUMOylation or deSUMOylation of ATXN7 could represent
potential targets for therapeutic intervention. A small molecule inducer
of the SUMO-activating enzyme E1 ligase has been found in a very
specific situation (Kho et al., 2015); however, most studies in the
SUMO field target inhibition of this pathway, of utmost importance in
the cancer field (He et al., 2017). SUMO E3 ligases may be key actors
to keep the right balance between normal protein homeostasis, and
deregulation of degradation pathways that lead to neuronal dysfunction
and neurodegeneration. There are no pharmacological molecules to
induce the PIAS proteins (even fewer to target brain). Design of viral
vectors expressing PIAS proteins could be a possible strategy to
induce, in brain, a high percentage of SUMOylated ATXN7. As IFN-
beta acts on both upregulating PML clastosomes (Chort et al., 2013),
and boosts the SUMO2/3-conjugated protein levels in cerebellum (as
indicated in this study), we propose that it could be the best therapeutic
agent acting on two complementary pathways to finally target and
degrade mutant ATXN7 via the proteasome.
MATERIALS AND METHODS
Plasmids and site-directed mutagenesis
All ATXN7 constructs contain full-length ATXN7 as described (Janer et al.,
2006, 2010; Zander et al., 2001). ATXN7-100Q was cloned in the Clontech
EGFP-N1 vector (Zander et al., 2001). ATXN7-72Q mutant KR is mutated
at position K257 identified as the major SUMO site (Janer et al., 2010). The
ATXN7-72Q 7KR mutant contains seven lysines mutated into arginine at
the following positions: 117, 223, 226, 257, 287, 321 and 858. FLAG-
SUMO2-pSG5, HA-SUMO2-pSG5 and plasmids coding for wild-type and
mutant RNF4 in the four SIMs and in the RING finger were all cloned in
pSG5. The SIM mutations were those described by Tatham et al. (2008):
RNF4 dSIM corresponds to mutated SIM1 (I40A, L42A and V43A),
mutated SIM2 (I50A, V51A and L53A), mutated SIM3 (V61A, V62A and
V63A) and mutated SIM4 (V71A, V72A, I73A and V74A). The RING
finger mutation (dHC) changes His160 to Ala and Cys163 to Ser. All
constructs were sequenced.
RNA interference
Dharmacon On Target Plus SMARTpools (Thermo Fisher Scientific) were
used for siRNA disruption of RNF4 (L-006557) and non-targeting siRNA
(D-001810). HeLa cells were seeded in six-well dishes at a density of
1.5×106 cells per well in Dulbecco’s modified Eagle medium (DMEM). The
next day, the cells were transfected with 75 pmol RNA in 4 μl RNAi Max
(Invitrogen), according to the manufacturer’s instructions. After 24 h, the
cells were transfected with 2 μg ATXN7-72Q using Lipofectamine 2000
(Invitrogen). After 48 h, the cells were harvested for preparation of whole
extracts or denaturing immunoprecipitation.
Primary antibodies
Antibodies used in western blot (WB), immunofluorescence (IF),
immunohistochemical (IHC) and immunoprecipitation (IP) analyses are
presented in Table S1.
Cell culture
HeLa, HEK293 and MCF7 cells were maintained in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum and penicillin-streptomycin
(100 UI/ml-100 µg/ml). Cell lines were purchased from American Type
Culture Collection (LGC Standards, France) and tested for mycoplasma
contamination. Cell lines were transfected with Lipofectamine 2000
(Invitrogen) as prescribed. Western blots were performed after 48 h of
expression. HeLa cells were analyzed by immunofluorescence 40-45 h post-
transfection. Depending on the analysis, cells were either scraped in PBS
containing N-ethyl maleimide (NEM), centrifuged and lysed, or lysed
directly in 2% SDS Laemmli sample buffer or, for immunoprecipitation,
lysed in denaturing buffer containing 1% SDS.
Cell lysate fractionation, mouse brain extracts, immunoblot and
filter retardation assay
Cells were washed and harvested in PBS supplemented with 20 mM NEM,
pelleted and lysed for 30 min on ice in lysis buffer containing 50 mM Tris-
HCl, pH 8.8, 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 1 mM EDTA,
20 mM NEM and 250 IU/ml benzonase (Merck) supplemented with a
cocktail of protease inhibitors (Complete and Pefabloc, Roche). Total
extracts were centrifuged at 16,000 g for 15 min at 4°C to separate soluble
proteins from aggregates. Supernatants were analyzed by immunoblotting
(NS fraction). Pellets were further incubated for 30 min on ice in a buffer
containing 20 mM Tris-HCl, pH 8.0, 15 mM MgCl2, and 250 IU/ml
benzonase. Mouse brain samples (cerebella, cortex, brainstem) were ground
(Tissue Lyser II, Quiagen) in ice-cold RIPA lysis buffer containing 50 mM
Tris-HCl, pH 8.8, 150 mMNaCl, 1 mM EDTA, 1% Na deoxycholate, 0.1%
SDS, 1% NP-40, 20 mM NEM and 250 IU/ml benzonase (Merck)
supplemented with protease inhibitors (Complete, Roche). Extracts
were sonicated (four pulses of 10 s) and centrifuged at 16,000 g for
15 min at 4°C, and supernatants were collected for immunoblotting.
Protein concentrations were determined by Bradford assay (Bio-Rad).
Samples containing 25 µg (HEK293, HeLa cell extracts) or 50 µg (mouse
brain extracts) of protein were resolved on pre-cast 4-12% (Invitrogen),
7.5% or 4-20% (Bio-Rad) gels, transferred onto nitrocellulose membranes
(Protran, Whatman) by liquid transfer for 1.5 h, stained with Ponceau
Red and blocked in 5% non-fat milk. Selected primary antibodies
were incubated with the membranes overnight at 4°C (Table S1);
horseradish peroxidase-conjugated or fluorescent secondary antibodies
were incubated for 2 h at room temperature. Membranes were then incubated
with enhanced chemiluminescence substrate (Pierce); chemiluminescence
or fluorescence signals were revealed on film (ECL, Amersham Hyperfilm)
or captured with an Odyssey Imaging (Li-COR) system. Densitometry was
carried out using ImageJ software (NIH). The pellet was analyzed in a filter
retardation assay (SR fraction): samples (40 µg) were boiled for 5 min in 2%
SDS buffer and filtered on a BRL dot-blot filtration unit through a cellulose
acetate membrane (Schleicher and Schuell, 0.2 µm pore size) equilibrated
with 0.1% SDS (Sittler et al., 1998; Wanker et al., 1999).
SUMO immunoprecipitation
SUMO immunoprecipitation (SUMO-IP) was performed as described
(Barysch et al., 2014; Becker et al., 2013). MCF7 cells were grown to
confluence in 15-cm dishes, with three plates per immunoprecipitation
condition (control, SUMO1, SUMO2). Cells were washed in cold PBS with
10 mM NEM. Then, 250 μl of 2× lysis buffer (1× PBS, 2% SDS, 10 mM
EDTA, 10 mM EGTA, 20 mM NEM, 2 mM Pefabloc and 2 μg/ml each of
aprotinin, leupeptin and pepstatin) was added to each plate and cells were
scraped. MCF7 lysates were sonicated and then boiled in 50 mM
dithiothreitol (DTT), followed by a 10-fold dilution in RIPA buffer.
SUMOylated ATXN7 in MCF7 lysates was immunoprecipitated with
antibody-coupled beads (mouse SUMO1, clone 21C7; mouse SUMO2,
clone 8A2) overnight at 4°C; SUMO-conjugates were elutedwith an excess of
epitope-spanning peptides to ensure specificity. A pre-elution step (without
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peptide) was followed by two elution steps (incubation with epitope-spanning
peptides: SUMO1 21C7, VPMNSLRFLFE; SUMO2 8A2, IRFRFDGQPI).
To concentrate endogenous SUMO-modified ATXN7, the eluted proteins
were precipitated with trichloroacetic acid. To analyze potential SUMO
targets, 40 μl (50%) of the precipitated eluate and 20 μl (0.2%) of the input
and flow-through were loaded on 5-20% SDS-PAGE gels.
In vivo SUMOylation and denaturing immunoprecipitation
HEK293 cells were transfected with HA-ATXN7-72Q, FLAG-SUMO-2
and additional constructs as indicated in the figures. At 32 h after
transfection, cells were treated with 1 μM epoxomicin or DMSO for 16 h,
and harvested in 100 μl IP-lysis buffer containing 50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.5% NP-40, 0.5% Triton X-100, 10 mM NEM,
supplemented with 1% SDS, 50 mM DTT, 250 IU/ml benzonase and
protease inhibitors. For denaturing immunoprecipitation (d-IP), cell lysates
were boiled at 95°C for 10 min. One aliquot (5%) of input was saved for
western blot analysis. The remaining lysate was diluted 10-fold in IP-lysis
buffer to reduce the SDS concentration. Lysates were centrifuged at
16,000 g for 15 min at 4°C. Protein concentrations were determined by BCA
assay (Pierce). Lysates (800 μg) were incubated with anti-HA beads (Sigma-
Aldrich, A2095) at 4°C on a rotator for 4 h or overnight. The beads were
washed four times with IP-lysis buffer and boiled in 60 μl 2% SDS Laemmli
buffer. Proteins eluted from beads were analyzed by immunoblotting with
anti-HA and anti-SUMO2 antibodies. To compare the levels of ATXN7
SUMOylated species, d-IP products were analyzed by immmunoblotting
after normalization to similar levels of unmodified ATXN7 by densitometry
with ImageJ.
Proximity ligation assay
Proximity ligation assay (Olink Bioscience) allows the detection of proteins
located in close proximity (<40 nm); it is based on the in situ proximity
ligation of DNA linked to secondary antibodies followed by PCR
amplification. Primary antibodies were anti-1C1 and anti-SUMO1, anti-
1C1 and anti-SUMO2/3, anti-ATXN7 and anti-T7 tag. The specificity of the
PLA signal was confirmed by the lack of signal in cells treated with
detection probes (PLA+ and PLA−) and one of two antibodies (anti-1C1 for
ATXN7 protein, or anti-SUMO2/3 for SUMO2).
Animals
Heterozygous Atxn7100Q/5Q knock-in mice carrying 100Q CAG repeats in the
mouse Sca7 locus on the pathological allele, kindly provided by Prof.
H. Zoghbi (Baylor College ofMedicine, Houston, TX, USA), were housed in
a temperature-controlled room and maintained on a 12 h light/dark cycle
(Chen et al., 2012). Food and water were available ad libitum.
Immunohistochemical analyses were performed at 12 months of age (late-
stage disease), compared with 12-month-old wild-type littermates. Western
blot analyses from the cerebella and cortex of Atxn7100Q/5Q mice (n=4, 2
males, 2 females) compared with wild-type littermates (n=4, 2 males, 2
females) were performed at 12 months. Western blot analyses from
heterozygous SCA7266Q/5Q mice cerebella (11-week-old animals; n=4
MSA-treated and n=5 IFN-beta-treated males) were performed. Quantitative
RT-PCR of mRNA was performed in Atxn7100Q/5Q mice (n=5, 3 males, 2
females) (n=5, 2 males, 3 females) compared with wild-type littermates at 6
and 12 months (n=5 and n=5, respectively, 3 males, 2 females per group). For
the SCA7266Q/5Q knock-in line, we used RNA extracted from the cerebella of
n=5 MSA-treated and n=5 IFN-beta-treated males (heterozygous animals,
266Q/5Q), from 5 weeks of age until 11 weeks of age at sacrifice (Chort et al.,
2013), to perform quantitative RT-PCR. The experiments were carried out in
accordance with the European Community Council directive (86/609/EEC)
for the care and use of laboratory animals and were approved by the
Commission Génie Génétique of the French Ministry for Scientific Research
and Education (06/26/2010).
RNA purification and quantitative RT-PCR
Cerebella were dissected from 6- and 12-month-old Atxn7100Q/5Q mice and
wild-type littermates. Tissues were homogenized with an electric pestle
(Sigma-Aldrich) in QIAzol (Qiagen), and total RNA was isolated using
RNeasy® Lipid Tissue Mini kit (Qiagen) including an RNase-free DNase
step. The quality of total RNAwas controlled (Bioanalyzer 2100, Agilent).
Total RNA (1 μg) was reverse transcribed using the iScript cDNA synthesis
kit (Bio-Rad) according to the manufacturer’s instructions. mRNAs were
quantified by real-time RT-PCR in a Roche LightCycler LC480 sequence
detection system (Roche). Oligonucleotide primer pairs were obtained from
MWG Operon (France), designed with Oligo Explorer 1.0 and verified for
specificity with the NCBI Blast engine (www.ncbi.nlm.nih.gov/BLAST)
using the ‘nearly exact short match’ program (Table S2). The end-point PCR
(35 cycles) was performed with LightCycler 480 SYBER Green I Master
(Roche) on 20 ng reverse transcription product. After amplification, melting
curves for the PCR products were analyzed to confirm amplification
specificity. The relative levels of mRNA were standardized to Rplp0
ribosomal RNA, and to beta-2microglobulin (B2m) as non-variant RNA
species, according to Boda et al. (2009): forward primer for Rplp0
5′-GGCTGATCCATCTGCATTTGCG-3′; reverse primer for Rplp0 5′-
ATCTGATTCCTCCGACTCTTCCTTTG-3′; forward primer for B2m
5′-GCTATCCAGAAAACCCCTCAA-3′; reverse primer for B2m 5′-
CATGTCTCGATCCCAGTAGACGGT-3′. The primers of the SUMO
pathway – Pias1, Pias2, Pias3, Pias4, Senp1, Senp2, Senp3 and Senp6 –
were those published by O’Rourke et al. (2013). Each samplewas quantified
in triplicate. Expression levels were determined with the 2−ΔΔCT algorithm
following Applied Biosystem guidelines and Livak and Schmittgen (2001).
Immunofluorescence and confocal microscopy
HeLa cells were plated on poly-lysine (Sigma-Aldrich)-coated glass
coverslips. At 40-45 h post-transfection, cells were fixed for 20 min with
4% paraformaldehyde at room temperature, washed with PBS,
permeabilized in 0.1% Triton X-100 in PBS for 15 min, washed twice in
PBS, and blocked in 4% bovine serum albumin (BSA) in PBS for 1 h.
Primary antibodies (Table S1) were diluted in 4% BSA in PBS and
incubated overnight at 4°C. The cells were then washed three times in PBS,
and secondary antibodies, diluted in 4%BSA in PBS, were applied for 2 h at
room temperature and washed. Secondary antibodies were Alexa Fluor®
488-conjugated goat anti-mouse or goat anti-rabbit IgG (Invitrogen), Alexa
Fluor® 568-conjugated goat anti-mouse or goat anti-rabbit IgG (Invitrogen)
and Fluoprobes® 647-conjugated donkey anti-rabbit (Interchim), used at
1:500. The cells were then incubated with 4′,6-diamidino-2-phenylindole
(DAPI) diluted in PBS for 15 min, washed in PBS and mounted with
Fluorescent Mounting Medium (Dako). Confocal images were acquired at
room temperature with an Olympus BX 61 microscope equipped with ×60/
1.35 lens and a Fluoview FV-1000 image acquisition system. For Fig. 2B,
confocal images were acquired with a Leica SP5 inverted microscope
equipped with a ×63 lens and a Leica LAS image acquisition system. Images
were analyzed using ImageJ and the colocalization plugin JACoP (Just
Another Colocalization Plugin), as described in Bolte and Cordelier̀es (2006).
Human postmortem brain
Formalin-fixed, paraffin-embedded cerebellar tissue from two SCA7 patients
with morphologically and genetically confirmed SCA7 (57 and 10 years old
at death; with 47 CAG repeats and 85 CAG repeats on the mutant allele,
respectively), and a control subject with no evidence of neurological disease
(52 years old at death) were obtained from the Brain Bank of the Groningen
Medical Center (Groningen, The Netherlands) and from the Department of
Neuropathology of the Pitié-Salpêtrier̀e Hospital (Paris, France). All
experiments with human tissue were conducted under the ‘Code of
Conduct for dealing responsibly with human tissue in the context of health
research’ published by the Federation of DutchMedical Scientific Societies in
2011. The study was conducted in accordance with the Declaration of
Helsinki and all tissue donor patients provided written informed consent.
Immunohistochemical analysis
Mouse brain: mice received an overdose of sodium pentobarbital and were
perfused transcardially with 4% paraformaldehyde in 0.1 M PBS. The
brains were post-fixed in 4% paraformaldehyde for 24 h and cryoprotected
in 30% sucrose-PBS for 48 h at 4°C. Immunostaining was performed on
20-μm-thick frozen cryostat sections. Antigen retrieval, permeabilization
and blocking were performed as for human samples (see below). Sections
were incubated for 48 h at 4°C with primary antibodies (Table S1) followed
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by the appropriate Alexa Fluor® dye-conjugated secondary antibodies
(Invitrogen, 1:500): Alexa Fluor® 488-conjugated goat anti-rabbit
(ATXN7) and Alexa Fluor® 568-conjugated goat anti-mouse (SUMO2,
clone 8A2). Sections were incubated with DAPI, washed and mounted with
Fluorescence Mounting Medium (S3023, Dako).
Human brain: 5-μm sections were cut from paraffin-embedded brain
samples and stained with anti-ATXN7, anti-SUMO1, anti-SUMO2 and anti-
RNF4 antibodies. Antigens were retrieved by boiling the sections in 1 mM
citrate buffer, pH 6.0, in a microwave oven at 350 W. Sections were
permeabilizedwith PBS and 0.1%TritonX-100 and blocked by incubation for
2 h at room temperature in PBS containing 3% BSA, 4% normal goat serum,
0.1% Triton X-100. Sections were incubated for 48 h at 4°C with primary
antibodies (Table S1). Secondary antibodies for 3,3′-diaminobenzidine (DAB)
staining were biotinylated goat anti-rabbit or goat anti-mouse antibodies (BA-
9200, BA-1000, respectively; Vector Laboratories) at 1:250. DAB staining
was carried out with the Vectastain ABC kit (Pierce). Images of
immunostained sections were acquired with LAS V3.8 (Leica) software, at
room temperature, on a bright-field Leica DM 4000B microscope equipped
with a ×100/1.35 lens and a Leica DFC500 digital camera.
Statistical analysis
For statistical analysis, we performed either two-tailed Student’s t-tests (to
analyze imaging and biochemical data) or one-way ANOVA (to analyze
mRNA expression by quantitative RT-PCR) with Prism6 (GraphPad) and
with R software (https://www.r-project.org/); P<0.05 was considered
statistically significant.
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